1 unchanged sentence
Issuer Purchases of Equity Securities
−Removed: In August 2022, the Company announced that its Board of Directors had approved a three-year share repurchase program authorizing the repurchase of up to $300.0 million of Haemonetics common stock, based on market conditions, through August 2025.
−Removed: Under the share repurchase program, the Company is authorized to repurchase, from time to time, outstanding shares of common stock in accordance with applicable laws on the open market, including under trading plans established pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in privately negotiated transactions.
−Removed: In October 2024, the Company completed a $75.0 million repurchase of its common stock pursuant to an ASR entered into with Citibank in August 2024.
−Removed: The total number of shares repurchased under the ASR was 1.0 million at an average price per share upon final settlement of $74.36.
−Removed: As of December 28, 2024, the total remaining authorization for repurchases of the Company's common stock under the share repurchase program was $150.0 million.
−Removed: The following table provides information on the Company’s share repurchases during the third quarter of fiscal 2025:
+Added: The following table provides information on the Company’s share repurchases during the first quarter of fiscal 2026:
Total Number of Shares Purchased Average Price Paid per Share Total Number of Shares Purchased as Part of Publicly Announced Program Approximate Dollar Value of Shares that May Yet Be Purchased Under the Program (1)
−Removed: (in millions)($) (1)(2)
−Removed: September 29, 2024 – October 26, 2024
−Removed: — — — $ 150.0
−Removed: October 27, 2024 – November 23, 2024
−Removed: 209,494 71.60 209,494 150.0
−Removed: November 24, 2024 – December 28, 2024
−Removed: 209,494 209,494 $ 150.0
+Added: (Dollars in Thousands, Except Shares and Per Share Data)
+Added: March 30, 2025 – April 26, 2025 363,886 (2)
+Added: April 27, 2025 – May 24, 2025 — — — —
+Added: May 25, 2025 – June 28, 2025 — — — —
+Added: Total 363,886 363,886
+Added: (1) In August 2022, our Board approved a three-year share repurchase program authorizing the repurchase of up to $300.0 million of Haemonetics common stock, based on market conditions, through August 2025.
+Added: Under the 2022 share repurchase program, shares may be repurchased in accordance with applicable laws both on the open market, including under trading plans established pursuant to Rule 10b5-1 under the Exchange Act, and in privately negotiated transactions.
+Added: (2) In April 2025, the Company completed a $150.0 million repurchase of its common stock pursuant to an accelerated share repurchase agreement (“ASR”) entered into with Goldman Sachs & Co.
+Added: in February 2025.
+Added: The total number of shares repurchased under the ASR was 2,386,131 at an average price per share upon final settlement of $62.86.
+Added: As of March 29, 2025, the Company had fully funded the $300.0 million authorization under its 2022 share repurchase program.
Defaults Upon Senior Securities
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.